# Junta clínica — PT-pseudo_c03b1168ff4d (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_c03b1168ff4d",
  "pid": "PT-pseudo_c03b1168ff4d",
  "task": 1,
  "psa": 7.8,
  "age": 74,
  "months": 2,
  "pirads": "4",
  "psad": 0.165,
  "psav": 1.2,
  "psap": 6.3,
  "vol": 47.17,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.75055045,
  "medhx": "Hypertension, Hypercholesterolaemia, Chronic kidney disease",
  "meds": "valsartan, lisinopril, atorvastatin, simvastatin, rosuvastatin",
  "notes": "PSA 7.8 ng/mL. PI-RADS 4. PSAD 0.17. Prostate volume 47 mL. csPCa 0.75.",
  "pmhx": [
    "Hypertension",
    "Hypercholesterolaemia",
    "Chronic kidney disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "87 kg",
    "height": "184 cm",
    "bmi": "25.7",
    "bp": "143/82 mmHg",
    "hr": "81 bpm",
    "smoking": "Ex-smoker (34 pack-yr, quit 2006)",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "05 Jan 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Rising PSA levels combined with a previous positive biopsy mandate a current clinical reassessment."
    },
    {
      "s": "History",
      "t": "A confirmed prostate malignancy now requires surveillance, following initial PSA investigation in mid-2022. The subject is a 74-year-old ICT consultant who remains married and resides alone, though his adult son lives in close proximity. Tobacco use ceased in 2006, following a 34 pack-year accumulation. Physical activity remains high, comprising three weekly five-kilometre runs, with no alcohol consumption. Distance to the clinic exceeds 90 minutes, and telephone consultations are preferred. Lower urinary tract symptoms are pronounced, yielding an IPSS score of 26. Hypertension, hypercholesterolaemia, and chronic kidney disease form the background of his medical history. Current pharmacotherapy consists of valsartan, lisinopril, atorvastatin, simvastatin, and rosuvastatin. Recent preventive care included a routine colonoscopy and audiology evaluation, while his latest cardiology review returned unremarkable."
    },
    {
      "s": "Physical examination",
      "t": "Digital rectal examination yields normal findings: a symmetrically enlarged gland with a smooth, firm consistency and no palpable nodules or asymmetry. Vital sign measurements record 143/82 mmHg for blood pressure and 81 bpm for heart rate. A general physical assessment notes a BMI of 25.7, alongside clear pulmonary fields, a regular cardiac rhythm, and an absence of peripheral oedema."
    }
  ],
  "occupation": "ICT consultant",
  "marital": "Married",
  "living": "Lives alone; adult son nearby",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Gastroenterology — surveillance colonoscopy",
    "Audiology — hearing test"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 26/35 (severe LUTS)",
  "admin": "Lives >90 min from clinic; phone follow-up preferred where clinically safe.",
  "mri_hospital": "Spaarne Gasthuis (Haarlem)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c03b1168ff4d
Task: 1

Encounter: Urology - outpatient on 05 Jan 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 74-year-old male
  - PSA: 7.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.165 ng/mL²
  - PSA velocity: 1.2 ng/mL/yr
  - Prior PSA: 6.3 ng/mL
  - Prostate volume: 47.17 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.75055045 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia, Chronic kidney disease
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia, Chronic kidney disease
  - Current medication: valsartan, lisinopril, atorvastatin, simvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 7.8 ng/mL. PI-RADS 4. PSAD 0.17. Prostate volume 47 mL. csPCa 0.75.

Vitals: weight 87 kg, height 184 cm, BMI 25.7, BP 143/82 mmHg, HR 81 bpm. Smoking: Ex-smoker (34 pack-yr, quit 2006).

Chief complaint: Rising PSA levels combined with a previous positive biopsy mandate a current clinical reassessment.

History: A confirmed prostate malignancy now requires surveillance, following initial PSA investigation in mid-2022. The subject is a 74-year-old ICT consultant who remains married and resides alone, though his adult son lives in close proximity. Tobacco use ceased in 2006, following a 34 pack-year accumulation. Physical activity remains high, comprising three weekly five-kilometre runs, with no alcohol consumption. Distance to the clinic exceeds 90 minutes, and telephone consultations are preferred. Lower urinary tract symptoms are pronounced, yielding an IPSS score of 26. Hypertension, hypercholesterolaemia, and chronic kidney disease form the background of his medical history. Current pharmacotherapy consists of valsartan, lisinopril, atorvastatin, simvastatin, and rosuvastatin. Recent preventive care included a routine colonoscopy and audiology evaluation, while his latest cardiology review returned unremarkable.

Physical examination: Digital rectal examination yields normal findings: a symmetrically enlarged gland with a smooth, firm consistency and no palpable nodules or asymmetry. Vital sign measurements record 143/82 mmHg for blood pressure and 81 bpm for heart rate. A general physical assessment notes a BMI of 25.7, alongside clear pulmonary fields, a regular cardiac rhythm, and an absence of peripheral oedema.

Patient info: ICT consultant; Married; Lives alone; adult son nearby.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Running 3x/week, 5 km; IPSS score: 26/35 (severe LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Audiology — hearing test.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.57
  uncertainty  +/- 0.14 epistemic (95% band 0.30-0.83); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.02: PI-RADS 4, PSA 4.5, PSAD 0.08, age 73, DRE Normal -> BIOPSY (borderline). He wrote: "Favourable risk intermediate risk PC in 73 yr old. Unclear when previous MRI+bx was performed. Reasonable to recommend another biopsy approx 2yrs after the first, especi…"
  2. distance 1.08: PI-RADS 4, PSA 6.7, PSAD 0.2, age 67, DRE Normal -> BIOPSY (borderline). He wrote: "Active surveillance, only one previous biopsy 2 yrs ago. Stable findings (stable PIRADS4, slightly increasing PSA) -> borderline indication for biopsy. As only one previ…"
  3. distance 1.12: PI-RADS 4, PSA 4.1, PSAD 0.181, age 72, DRE Normal -> BIOPSY (borderline). He wrote: "Borderline older patient, favorable intermediate risk disease with perineurial features. Low PSA (why was he biopsied in 2023 under non-elevated PSA?). While only one pr…"

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI is mandated to confirm histological progression before a change in treatment strategy. A stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline makes the decision dependent on the MRI findings and the PSA density threshold. The panel variables alone do not settle the indication for a repeat biopsy. The precedent suggests that the decision is heavily influenced by the documented grade of the prior biopsy and surveillance history, which is a fact that no panel variable represents.

WHAT WE STILL NEED
The prior biopsy status is documented as "Positive" on the panel, which is a fact that makes it decisive. The documented grade of the prior biopsy (Gleason or ISUP) and the number and dates of biopsy sessions in the notes are needed to determine the next step. The PSA value of 7.8 ng/mL is known, and the PI-RADS score of 4 is known, but the guideline requires the histological findings to guide the decision.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges entirely on the documented grade and history of the prior biopsy, as the guideline requires histological findings to guide the next step.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What was the prior biopsy grade (Gleason/ISUP), the number and dates of biopsy sessions, and the surveillance protocol status?
  laboratory_results (get_lab_results) -> What are the full panel results, including free-PSA fraction, renal function, and haemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason or ISUP) of the prior positive biopsy?
  Q2. What is the number and dates of previous biopsy sessions, and is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion size and zone is roughly "14 x 11 x 16 mm" in the left peripheral zone. Extraprostatic extension is "no evidence of extracapsular extension". Comparison against an earlier study is "new".
psa_trend
The serial PSA value trend is rising, with values at "Jun 2022" of "1.5 ng/mL", "Sep 2023" of "3.4 ng/mL", and "Jan 2025" of "7.8 ng/mL".
previous_notes
The prior biopsy grade is "positive" (no specific Gleason/ISUP grade recorded). There is "one" biopsy session recorded, dated "16 Jan 2023". The surveillance protocol status is "Ongoing monitoring for established prostate cancer".
laboratory_results
The full panel results include "PSA" of "7.8 ng/mL" on "14 Dec 2024", "Free PSA" of "1.59 ng/mL" on "14 Dec 2024", "%Free PSA" of "20%" on "14 Dec 2024", "Creatinine" of "136 umol/L" on "14 Dec 2024", and "eGFR" of "<60 mL/min/1.73m2" on "14 Dec 2024".

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes already detailed the relevant history regarding the prior diagnosis and surveillance.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS score of "4" on the MRI.
Rising PSA trend from "3.4 ng/mL" to "7.8 ng/mL".
The EAU guideline suggests a repeat biopsy to confirm histological progression.
Findings that argue AGAINST sampling this patient now:
The prior biopsy grade is not recorded.
The patient is currently on an "Ongoing monitoring" surveillance protocol.

WHERE THIS LEANS
The findings suggest a need for further histological confirmation due to the rising PSA and PI-RADS 4 finding, which aligns with the EAU guideline's requirement for histological confirmation.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 7.80 ng/mL over 3 points spanning 31 months; velocity +2.45 ng/mL per year; doubling time about 13 months.
PROJECTION at 6 months: 11.8 ng/mL, conformal 95% band 3.4-41.2.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.53
  uncertainty  +/- 0.11 epistemic (95% band 0.31-0.75), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.57  ('discuss' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.53  ('discuss' tier, fusion_full)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.62 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—directly address the moderator's questions regarding the prior biopsy grade and surveillance status.

ALIGNMENT WITH THE PANEL
The panel protocol concluded with a BIOPSY based on a weighted vote, noting that the documented prior grade was not recorded in the opened documents. The retrieved information confirms a rising PSA trend and a PI-RADS 4 finding, which supports the need for further histological confirmation as suggested by the EAU guideline.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason or ISUP) of the prior positive biopsy? This remains unanswered, as the previous_notes stated the grade was "positive" but did not specify Gleason/ISUP.
Q2. What is the number and dates of previous biopsy sessions, and is the patient currently on a surveillance protocol with a confirmatory biopsy due? The previous_notes state "one" biopsy session on "16 Jan 2023" and "Ongoing monitoring for established prostate cancer."

WHAT CARRIES WEIGHT, AND WHY
The rising PSA trend (from 1.5 to 7.8 ng/mL) and the PI-RADS 4 finding are highly relevant as they indicate disease progression or increased suspicion. The lack of a documented prior biopsy grade is the critical missing piece that prevents a definitive decision based on the EAU guideline's requirement for histological progression confirmation.

MY SUGGESTION TO THE CHAIR
Given the rising PSA trend and the PI-RADS 4 finding, and the EAU guideline's emphasis on histological confirmation for progression, I suggest proceeding with a repeat biopsy to obtain the necessary histological grade information.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

A repeat biopsy is indicated because the rising PSA trend from 1.5 to 7.8 ng/mL and the PI-RADS 4 finding align with the EAU guideline's requirement for histological confirmation of progression. The critical missing piece was the documented prior biopsy grade, which was not recorded in the opened documents. The evidence converged on the need for further histological confirmation due to the rising PSA and MRI findings.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
